These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8685069)

  • 1. A comparison of the activity of a heparan sulphate of defined molecular weight range (7500-15,000 Da) with heparin and dermatan sulphate.
    Gervasi GB; Catalani R; Bartoli C; Carpita G; Farina C; Gelso E
    Pharmacol Res; 1995 Jun; 31(6):331-6. PubMed ID: 8685069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
    Hoppensteadt D; Walenga JM; Fareed J
    Thromb Res; 1990 Nov; 60(3):191-200. PubMed ID: 2084948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
    Ofosu FA; Modi GJ; Blajchman MA; Buchanan MR; Johnson EA
    Biochem J; 1987 Dec; 248(3):889-96. PubMed ID: 2963622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma anticoagulant mechanisms of heparin, heparan sulfate, and dermatan sulfate.
    Ofosu FA; Buchanan MR; Anvari N; Smith LM; Blajchman MA
    Ann N Y Acad Sci; 1989; 556():123-31. PubMed ID: 2525356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anticoagulant effect of heparan sulfate and dermatan sulfate.
    Teien AN; Abildgaard U; Höök M
    Thromb Res; 1976 Jun; 8(6):859-67. PubMed ID: 134464
    [No Abstract]   [Full Text] [Related]  

  • 6. Dermatan sulfate and LMW heparin enhance the anticoagulant action of activated protein C.
    Fernández JA; Petäjä J; Griffin JH
    Thromb Haemost; 1999 Nov; 82(5):1462-8. PubMed ID: 10595639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers.
    Tripodi A; Moia M; Bottasso B; Tenconi PM; Gianese F; Mannucci PM
    Thromb Res; 1991 Jun; 62(6):663-72. PubMed ID: 1926059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
    Ofosu FA
    Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The additive effect of low molecular weight heparins on thrombin inhibition by dermatan sulfate.
    Cosmi B; Agnelli G; Young E; Hirsh J; Weitz J
    Thromb Haemost; 1993 Sep; 70(3):443-7. PubMed ID: 8259546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antithrombotic properties of dermatan sulphate in a rat venous thrombosis model.
    Maggi A; Abbadini M; Pagella PG; Borowska A; Pangrazzi J; Donati MB
    Haemostasis; 1987; 17(6):329-35. PubMed ID: 3428718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human platelet factor 4 and protamine sulphate interaction with glycosaminoglycans in the rabbit.
    Cella G; Myers CJ; Prosdocimi M; Sasahara AA
    Eur J Clin Invest; 1987 Dec; 17(6):548-54. PubMed ID: 3123254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf.
    Cella G; Scattolo N; Luzzatto G; Stevanato F; Vio C; Girolami A
    J Med; 1986; 17(5-6):331-46. PubMed ID: 2953835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides.
    Wun TC
    Blood; 1992 Jan; 79(2):430-8. PubMed ID: 1346095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits.
    Ishida M; Nakada Y; Horiuchi M; Sakamoto F
    Arzneimittelforschung; 1998 Aug; 48(8):818-21. PubMed ID: 9748709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents.
    Merton RE; Thomas DP
    Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and chronic effects of a new low molecular weight dermatan sulphate (Desmin 370) on blood coagulation and fibrinolysis in healthy subjects.
    Legnani C; Palareti G; Biagi R; Ludovici S; Maggiore L; Milani MR; Coccheri S
    Eur J Clin Pharmacol; 1994; 47(3):247-52. PubMed ID: 7867677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein.
    Calabrese GC; Alberto MF; Tubio R; Marani MM; Fernández De Recondo ME; Lazzari M; Recondo EF
    Thromb Res; 2004; 113(3-4):243-50. PubMed ID: 15140589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
    Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
    Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic properties of a low molecular weight dermatan sulfate: comparison with unfractionated dermatan sulfate.
    Dol F; Petitou M; Lormeau JC; Choay J; Caranobe C; Sie P; Saivin S; Houin G; Boneu B
    J Lab Clin Med; 1990 Jan; 115(1):43-51. PubMed ID: 2299256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological actions of sulodexide.
    Ofosu FA
    Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.